Advanced Cell Diagnostics Inc. (ACD), a technology and market leader in the field of molecular pathology and developer of cell and tissue-based analysis tools, has announced the establishment of a European subsidiary which will start business in October 2014.
The move comes shortly after the company announced its probe library had grown to over 4000 probes and is indicative of the growing international demand for RNAscope® assays. The assays represent a major technological advance for in situ RNA detection, enabling robust single RNA molecule detection for the first time in formalin-fixed, paraffin-embedded (FFPE) tissue. Since their commercialisation three years ago, these assays have been adopted across the globe by major pharma biotech companies and leading research institutions for drug discovery, translational research, and the development of clinical and companion diagnostic tests.
The news also highlights ACD’s continued commitment to providing exceptional customer service to its global customers; “ACD is very excited about the rapid expansion of our customer base in Europe,” said ACD’s Chief Operating Officer Steve Chen. “Establishing a local subsidiary is a natural next step for us to extend our market presence and provide a faster and enhanced level of service to our customers here.”
The ACD European subsidiary has a warehousing and distribution centre located close to Milan, Italy, and sales, marketing and technical support staff in Germany and the UK. Such an arrangement offers significant benefits to European customers and eliminates troublesome and unpredictable import/export border issues. Product delivery becomes faster and more reliable with urgent orders of in-stock items able to be shipped next-day within Europe. In addition, customers will be able to place orders in Euros and technical and logistic support will be provided locally within the same time zone.
For further information, please visit www.acdbio.com.